Add BrightSurf on Google Email

Immunology Frontier Research Center (IFReC) - Osaka University


Unveiling the identity of Crohn's disease T cells

Researchers at Osaka University have identified transcription factors RUNX2 and BHLHE40 as crucial for inducing T cells involved in Crohn's disease. Overexpression of these factors promotes inflammatory cytokine production and tissue-retentive properties, making them potential novel therapeutic targets.

SourceImmunology Frontier Research Center (IFReC) - Osaka University·JournalJournal of Experimental Medicine·TypeExperimental study·DateSep 4, 2025

How PM2.5 wrecks your airways and how the damage might be reversed

Exposure to PM2.5 air pollutants impairs mucociliary clearance, a key protective mechanism in the respiratory tract, leading to severe airway damage and respiratory diseases. Researchers have identified the enzyme ALDH1A1 as a potential therapeutic target to reverse this damage and strengthen our respiratory defenses.

SourceImmunology Frontier Research Center (IFReC) - Osaka University·JournalJournal of Clinical Investigation·TypeExperimental study·DateJun 2, 2025

Study reveals how our gut cells detect harmful invaders

Researchers from Osaka University discovered that the GPR31 receptor in gut surveillance cells detects bacterial metabolites and triggers immune responses, which could lead to new drug developments and probiotic treatments. The study also found that these receptors play a key role in the immune response to gut infections in humans.

SourceImmunology Frontier Research Center (IFReC) - Osaka University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateOct 22, 2024

Pulling out the stops: Deletion of regnase-1 promotes anti-tumor activity in NK cells

Research reveals that deletion of Regnase-1 in mice enhances NK cell anti-tumor activity by up-regulating Ifng mRNA through OCT2-dependent transcription. This approach could lead to synergistic enhancement of therapeutic efficacy against solid tumors when combined with current immunotherapies.

SourceImmunology Frontier Research Center (IFReC) - Osaka University·JournalImmunity·TypeExperimental study·DateMay 30, 2024